Arcus Biosciences has had a mixed share price record over the past few years, and the latest pullback puts a spotlight on a simple question for you as an investor: Is the current valuation of Arcus supported by the cash the business is expected to generate over time, based on a Discounted Cash Flow (DCF) view of its prospects?
- Over the past 5 years the stock has fallen 49.1%, which puts long term cash generation and the price you are paying for those future flows under closer scrutiny.
- Recent updates around casdatifan, including expectations for broader use in kidney cancer and a cash runway projected into 2029, may support a longer period of investment before any potential payoffs from commercial cash flows show up.
- Prefer to judge Arcus Biosciences on sales? See why Arcus Biosciences's 27.1x P/S tells a different valuation story.
The issue now is whether Arcus Biosciences' current share price is adequately explained by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.
If you are weighing whether Arcus Biosciences' recent pullback is justified by its cash flows, it can help to line it up against other companies screened for 32 high quality undervalued stocks
Is Arcus Biosciences a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here is built from Arcus Biosciences' projected free cash flows to equity over two stages. Over the last twelve months the business reported a free cash outflow of about $467.3 million, and analyst forecasts keep cash flows in negative territory for several more years before a turn to positive figures around 2030 and beyond.
Because the projections assume Arcus Biosciences shifts from sizeable cash burn to growing positive free cash flows in the next decade, most of the estimated intrinsic value comes from that long term phase rather than the near term losses. Despite recent third quarter 2026 news pointing to progress for casdatifan and a cash runway into 2029, the share price of $18.80 still values the equity below what this DCF model implies the cash flows are worth over time. Find out what Arcus Biosciences could be worth using our Discounted Cash Flow (DCF) estimate.
The Arcus Biosciences Narrative: What Would Justify Today's Price?
Narratives for Arcus Biosciences pick up where the DCF puzzle leaves off and spell out what path for growth, profitability and earnings would need to play out for the share price to end up meaningfully higher or lower than it is today on Simply Wall St's Community page. Each scenario ties its number to a clear view on how Arcus Biosciences' growth, margin profile and key risks might evolve. This gives you a reference point to revisit as fresh information comes through.
One of the top narratives on Arcus Biosciences: 54% undervalued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"The current valuation implies the market is heavily discounting Arcus Biosciences’ guided RCC revenue opportunity for casdatifan, the planned Phase III expansion and the emerging oral immunology pipeline..."
Discover why this Narrative puts Arcus Biosciences at 54% undervalued.
One more essential check for Arcus Biosciences beyond the cash flow math
Before you stop at the DCF and price screens, it is worth asking who is steering Arcus Biosciences, how their pay is structured, and whether those incentives line up with your interests. See who runs Arcus Biosciences and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com